All Posts By

laurabbook@gmail.com

OncLive
ADC-, Bispecific Antibody–Based Therapies Help Build a New Treatment Paradigm in EGFR+ NSCLC ResearchTreatments

ADC-, Bispecific Antibody–Based Therapies Help Build a New Treatment Paradigm in EGFR+ NSCLC

*July 2025* Osimertinib's approval for NSCLC post chemoradiation is supported by the LAURA trial, showing improved overall survival compared with placebo. The ORCHARD study is evaluating osimertinib with datopotamab deruxtecan, demonstrating promising progression-free survival and response rates in EGFR-mutated NSCLC. The MARIPOSA trial showed that amivantamab plus lazertinib offers an…
laurabbook@gmail.com
March 24, 2026
OncLive
Frontline Iza-Bren Plus Osimertinib Elicits 100% ORR in EGFR-Mutant NSCLC ResearchTreatments

Frontline Iza-Bren Plus Osimertinib Elicits 100% ORR in EGFR-Mutant NSCLC

*September 2025* Key Takeaways Iza-bren plus osimertinib achieved a 100% objective response rate in EGFR-mutated NSCLC, with a confirmed ORR of 95% at a 2.5 mg/kg dose. The 12-month progression-free survival and overall survival rates were 92.1% and 94.8%, respectively, indicating strong efficacy. The treatment was well-tolerated, with hematologic adverse…
laurabbook@gmail.com
March 24, 2026
Bonnie Addario
AdvocacyStories

Tribute to Bonnie Addario

Written by Colleen Sturdivant Many in this community are likely familiar with Bonnie Addario and her positive impact on the lung cancer community. But many of you may not know that Bonnie was an early supporter of the EFGR Resisters. I became aware of the Bonnie J. Addario Lung Cancer…
laurabbook@gmail.com
March 24, 2026
Onc Live
FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC ResearchTreatments

FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC

*September 2025* Key Takeaways Iza-bren targets EGFR and HER3, showing potential in treating EGFR-mutant NSCLC after progression on EGFR TKI and platinum-based chemotherapy. The FDA's breakthrough therapy designation highlights iza-bren's potential to improve clinical outcomes for previously treated EGFR-mutated NSCLC patients. Clinical trials focus on determining the recommended phase 2…
laurabbook@gmail.com
February 20, 2026
BBC logo
Advocacy

The mystery rise of lung cancer in non-smokers

*June 2025* The number of lung cancer cases in people who have never smoked is increasing. The disease is different from lung cancer caused by smoking, so what causes it? Martha first realised that something was wrong when her cough changed and the mucus in her airways became increasingly viscous.…
laurabbook@gmail.com
November 21, 2025
Science Direct
ResearchTreatments

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma

*June 2025* Abstract Introduction Dysregulated MET signaling, such as MET overexpression or MET amplification (METamp), is a important mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant lung adenocarcinoma (LUAD). Combination therapy with EGFR TKIs and MET TKIs has revealed efficacy in these patients. This study…
laurabbook@gmail.com
November 20, 2025
Journal of Thoracic Disease
ResearchTreatments

Efficacy evaluation of tyrosine kinase inhibitors for advanced non-small cell lung cancer patients with leptomeningeal metastasis

*May 2025* Background: Leptomeningeal metastasis (LM) is an infrequent and challenging site of metastasis in patients with non-small cell lung cancer (NSCLC). Currently, there is no standardized treatment protocol or consensus for managing NSCLC patients with LM. This study aims to comprehensively evaluate the efficacy and safety of targeted therapy in…
laurabbook@gmail.com
November 20, 2025
OncLive
ResearchTreatments

First-Line Osimertinib Plus Chemo Boosts OS in EGFR+ NSCLC

*July 2025* First-line treatment with the combination of osimertinib (Tagrisso) in combination with chemotherapy led to a statistically significant and clinically meaningful improvement in overall survival (OS) compared with osimertinib alone in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR mutations, according to data from…
laurabbook@gmail.com
November 20, 2025
OncLive
ResearchTreatments

FDA Grants Fast Track Designation to Next-Generation HER3-Directed ADC for EGFR+ Advanced NSCLC

*July 2025* The FDA has granted fast track designation to the next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310 for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) harboring an EGFR exon 19 deletion or exon 21 L858R mutation who experienced disease progression on or after…
laurabbook@gmail.com
November 20, 2025